Guidelines for Anticoagulation in Paediatric Cardiac Patients
|
|
- Amice Woods
- 5 years ago
- Views:
Transcription
1 Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe cyanosis Receiving Aspirin / Dipyridamole / Clopidogrel Stop aspirin / dipyridamole 2 days prior to surgery (i.e. if the child s operation is on Tuesday, then their last dose of aspirin / dipyridamole will be on Saturday). Admit the day before for intravenous fluids +/- intravenous heparin depending on the haematocrit. It is significant if it is greater than Start heparin (prophylactic) at 10units/Kg/hour. Check APTT at 4 hours, if below 85 continue at same rate. At the unlikely event of APTT greater than 85 stop heparin and recheck APTT in 1hour. Discuss results with paediatric cardiology consultant/registrar. Check APTT daily, 4 hours after syringe changes. MVR / AVR on Warfarin Stop warfarin 2 days prior to surgery (i.e. of the child s operation is on Tuesday, then their last dose of warfarin will be on Saturday). The INR will need to be checked on the day of admission, the day before the operation. If the INR is between , then no further anticoagulation treatment is required prior to the operation. However if the INR is less than 1.5 then a stat dose of therapeutic tinzaparin (see page 9) should be given that evening, the day before the operation. Check APTT daily, 4hours after syringe changes Fontan Circulation on Warfarin Stop warfarin 2 days prior to surgery (i.e. of the child s operation is on Tuesday, then their last dose of warfarin will be on Saturday). Note: Stop Heparin Infusion 6hrs prior to surgery Post operative Management Blalock-Taussig Shunt (BT) / Sano Shunt / Hybrid procedure stent THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start prophylactic Heparin (see page 7) 2 hours post operation, unless there are bleeding issues. Start heparin (prophylactic) at 10units/Kg/hr (No loading dose) Check APTT after 4hrs, if less than 85 continue at the same rate. In the unlikely event that the APTT is greater than 85 discuss with surgeon or intestivist. Check APTT daily, 4 hours after syringe change. Start aspirin once patient tolerating feeds. Overlap heparin and aspirin until the 2 nd dose of aspirin is given (24hrs) and then stop the heparin. 1
2 Fontan Completion THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start prophylactic Heparin (see page 7) 2 hours post operation, unless there are bleeding issues. Start heparin (prophylactic) at 10units/Kg/hr (No loading dose) Check APTT after 4hrs, if less than 85 continue at the same rate. In the unlikely event that the APTT is greater than 85 discuss with surgeon or intestivist. Check APTT daily, 4 hours after syringe change. The day after surgery stop the heparin and after 2 hours start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 9). Antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 8). Start warfarin at 100microgram/Kg (max. 5mg) daily, the next day if extubated, stable and tolerating feeds. Check INR prior to starting warfarin and if greater than 1.8 discuss dosing of warfarin with the surgeons. Check INR before 2 nd dose and adjust dose accordingly. Then continue monitoring INRs daily and adjusting dose accordingly until the INR is stable. Once the INR is greater than 2, then the tinzaparin can be stopped. INR range is 2 to 3, target INR is 2.5 MVR / AVR THIS IS STANDARD TREATMENT (Any deviations from this will be decided by the surgeon and documented clearly) Start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 9) the morning after the operation. Antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 9). Start warfarin at 100microgram/Kg (max. 5mg) daily, the next day if extubated, stable and tolerating feeds. Check INR prior to starting warfarin and if greater than 2 discuss dosing of warfarin with the surgeons. Check INR before 2 nd dose and adjust dose accordingly. Then continue monitoring INRs daily and adjusting dose accordingly until the INR is stable. Once the INR is greater than 2, then the tinzaparin can be stopped. MVR; INR range is 2.5 to 3.5, target INR is 3 AVR; INR range is 2 to 3, target INR is 2.5 Removal of Pacing Wires Stop heparin 6 hours prior to pacing wire removal, or stop tinzaparin 12 hours prior to pacing wire removal. Make sure the INR is equal to or less than 2.5, before the pacing wires are removed. Removal of Chest Drains If the INR is equal to or greater than 2.5, discuss with the paediatric cardiothoracic consultant. Note: The above are general guidelines only. Each patient should be treated on an individual basis in consultation with the paediatric cardiothoracic consultant. 2
3 Management of On X Plus (ONX) Aortic Valve Whilst on PICU follow the guidelines for MVR/AVR Once the patient returns to the paediatric cardiology ward the following pathway should be followed: The patient should already be on therapeutic tinzaparin and warfarin. Continue therapeutic tinzaparin (see page 9) until the INR is greater than 2. Once the INR is above 2, STOP the tinzaparin. Once the patient is tolerating enteral feeds, then start oral aspirin 5mg/Kg/dose daily (maximum of 75mg daily), this is life-long. Note; this is additional to warfarin treatment. The INR range for these patients is 2 to 3 for the first 90 days and then after this time it drops to 1.5 to 2.5. These patients will be discharged home on both aspirin and warfarin. Please make it clear on the warfarin clinic referral form that the INR range will need to be reduced after 90 days. 3
4 MEDICAL PATIENTS Anticoagulation management: Indication Blalock-Taussig Shunt / Sano Shunt/ Hybrid procedure stent Clot in the IVC/SVC/Intracardiac, extensive clots in femoral vein Femoral artery spasm following catheterisation Elective cardioversion Cardiomyopathy patient with intracardiac clots Cardiomyopathy patient with no intracardiac clots Cardiomyopathy patient with arrhythmias Kawasaki Ablation ASD device (Amplatz septal occlude, Gore device, Occlotech device) or VSD device (various) Melody valve Insertion of duct stent by cardiac catheter or right ventricular outflow tract stent Treatment Aspirin (po) 5mg/kg/dose (max. 75mg) daily (Note:post-surgery - heparin) Tinzaparin for at least 3 months starting with therapeutic heparin treatment (page 7) if necessary Start heparin at 20units/Kg/hour do not load as will have received loading dose during catheter case. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar. Discuss with cardiologist if perfusion is not improved within 4 hours, consider therapeutic treatment dose of heparin (page 7) or thrombolysis (see thrombolysis protocol and only use in conjunction with the interventional consultant responsible). Perform TOE if there is a 48 hour history or arrhythmias. If no intracardiac clots present proceed to cardioversion. If clots present anticoagulate with warfarin and cardiovert at the discretion of the cardiologist (sometimes anticoagulate for 3 months prior to procedure) INR range 2 to 3 (target INR=2.5) Start both therapeutic heparin treatment (see page 7) and warfarin at 200microgram/Kg (max. 10mg) and then monitor INR and adjust dose accordingly. Once INR is in therapeutic range, stop the heparin. Start aspirin at 5mg/kg/dose daily (max. 75mg) If warfarin required aim for INR range 2 to 3 1 month of Aspirin (po) 5mg/kg/dose (max. 75mg) daily Start Aspirin (po) 5mg/kg/dose (max. 75mg) daily for 1 week before procedure and then for 6 months after Aspirin at 5mg/kg/dose (max. 75mg) daily for at least 6 months Start heparin (prophylactic, see page 6)) at 10units/Kg/hour. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar. Overlap with Aspirin (po) 5mg/kg/dose (max. 75mg) daily for 1 day. If child is normally fully anticoagulated prior to procedure then discuss therapy with paediatric cardiologist. Occasionally full heparinisation is necessary but the interventional consultant will make a specific recommendation if this is necessary (usually when higher risk of thrombus such as competitive flows). 4
5 Children on Warfarin Indication MVR with INR less than 2 Treatment Start therapeutic treatment of subcutaneous tinzaparin (therapeutic) (see page 8). If the child is equal to or over 40Kg then antifactor Xa monitoring is not necessary, unless the child is in renal failure. If the child is less than 40Kg then antifactor Xa monitoring is required and dosage adjustment will be required as per levels (see page 8). Readjust dose of warfarin and reload. Check INR in 2 to 3 days AVR with INR less than 1.8 (Note if the patient has a ONX AVR, then the INR range is ; in these patients if the INR is constituently below 1.5, then contact the paediatric cardiologist) Fontan circulation with INR less than 1.8 Patient with arrhythmias with INR less than 2 Readjust dose of warfarin and reload. Check INR in 3 to 4 days Readjust dose of warfarin and reload if necessary. Check INR in 7 days Readjust dose of warfarin and reload if necessary. Check INR in 7 days Cardiomyopathy patient with intracardiac clots with INR less than 2 or nil by mouth (NBM) Cardiomyopathy patient with arrhythmias with INR less than 2 if on warfarin or nil by mouth (NBM) Readjust dose of warfarin and reload. Check INR in 3 to 4 days Readjust dose of warfarin and reload. Check INR in 3 to 4 days Dental procedure Discuss management with paediatric cardiologist / dentist. Usually aim for an INR less than 2.5. Titrate the warfarin dose as appropriate for warfarin indication and dental work. Pacemaker procedure Other surgery Discuss management with implanting paediatric cardiologist. If anticoagulated for a prosthetic heart valve then aim for an INR of without stopping warfarin Discuss management with paediatric cardiologist and surgeon. The surgeon needs to decide the acceptable INR required for surgery As a general rule, patients on warfarin for: 1. Fontan circulation - can stop warfarin for 3 days prior to surgery and then after surgery restart warfarin at patients maintenance dose once no signs of bleeding 2. AVR - can stop warfarin for 3 days prior to surgery and then after surgery restart warfarin, by giving a reload, followed by patients maintenance dose the next day, once no signs of bleeding 3. MVR- stop warfarin 3 days prior to surgery, measure INR daily. Start 5
6 therapeutic heparin when INR is less than 2. Give loading dose of heparin and start a continuous infusion and chase APTT according to guidelines (page 7). After surgery restart warfarin, by giving a reload, followed by patient s maintenance dose the next day, also start therapeutic subcutaneous tinzaparin (see page 8). Continue tinzaparin until the INR is 2 or above once no signs of bleeding Note; For complex congenital cardiac children with stents and shunts, these general rules may not apply and advice from the paediatric cardiologist will be required. Children on Aspirin Indication Cardiomyopathy patient with no intracardiac clots who is nil by mouth (NBM) BT shunt / conduit / Sano who is nil by mouth (NBM) Treatment Start heparin (prophylactic, see page 6)) at 10units/Kg/hour. Check APTT in 4hours, if greater than 85, then stop infusion and discuss with paediatric cardiologist/registrar Discuss management with paediatric cardiologist Definition of Intravenous Heparin for anti-coagulation Prophylactic anticoagulation of heparin: Heparin infusion to run at the rate of 10 units/kg/hour. The rate of heparin infusion does not need to be changed based on APTT level. Check clotting once daily to ensure APTT is not more than 85 secs. If APTT is greater than 85 secs, discuss with PICU Consultant, Cardiac Surgical Consultant or Paediatric Cardiologist. Therapeutic anticoagulation of heparin: Heparin infusion is used to achieve a therapeutic level for APTT (usually 60 to 85 secs). APTT should be measured 4 hours after commencing and making any changes to the infusion. Refer to therapeutic anticoagulation prescription chart for information regarding initial dose and further adjustments. 6
7 7
8 Intravenous Therapeutic Heparin Dosage Guidelines Check clotting screen prior to commencing heparin (APTT, PT and INR) Loading dose 75units/kg IV over 10 minutes Maintenance dose Children less than 1 years Children equal to or greater than 1 year 28 Units/kg/hr 20units/kg/hr Check APTT 4hrs post loading dose and after each alteration in dose APTT Value ACTION APTT less than 50 Bolus of 50units/kg and increase rate by 10% APTT Increase rate by 10% APTT Continue at same rate, check APTT, FBC daily. Check Potassium levels alternate days APTT Decrease rate by 10% APTT Stop Infusion for 30 minutes. Decrease Rate by 10% APTT greater than 120 Stop heparin for 1hour Recheck APTT, if greater than 120 reduce rate by 15% and check APTT in 4hrs To Prescribe Heparin for Therapeutic indications Use the paediatric heparin prescription chart To Reverse Effect Protamine as per guidelines on page 10 8
9 Low Molecular Weight Heparin (LMWH) Dosing: Check coagulation screen before administration TINZAPARIN Therapeutic Treatment Dose Prophylactic Dose 0 to 2 months 275units/Kg daily * See paediatric antithrombotic guideline for dose and monitoring 2 to 12 months 250units/Kg daily * 1 to 5 years 240units/Kg daily * 5 to 10 years 200units/Kg daily * 10 to 16 years 175units/Kg daily * Dose adjustment of treatment dose of LMWH Anti-Xa level (units/ml) Dose change (%) * See paediatric antithrombotic guideline for dose and monitoring (on Leeds health pathways) To Reverse Effects Protamine as per guidelines on page 10 Low molecular weight heparins in renal impairment and liver impairment. The use of unfractionated heparin may be a preferable option in renal or liver dysfunction. If low molecular weight heparin is used consider reducing dose, increasing the frequency of monitoring anti-xa levels and adjusting dose accordingly. Patients with a creatinine clearance of less than 30mL/min should receive an initial 50% dose reduction. The anti-xa level should be measured after the first dose, further monitoring and dose modifications should follow the suggested guidance. 9
10 Reversal of Heparin with Protamine Heparin Protamine Dose Time since last dose (min) < 30 1 mg per 100units heparin received mg per 100units heparin received mg per 100units heparin received > mg per 100units heparin received Maximum Dose 50mg Infusion Rate 10mg/mL, Solution should not exceed 5mg/min Treatment of Warfarin induced bleeding Major Bleeding (Limb or Life Threatening) 1. Stop Warfarin 2. Give Phytomenadione (Vitamin K1) by slow IV injection 0 to 12 years old: 50 to 100 micrograms/kg Over 12 years old: 5 to 10 mg 3. Give Prothrombin Complex Concentrate (PCC) (Factors II, VII, X) 25units/Kg or if not available Fresh Frozen Plasma (FFP) 15mL/Kg 4. Exclude local cause of bleeding INR greater than 8 no bleeding or minor bleeding 1. Stop Warfarin, restart when INR is less than 5 2. If other risk factors for bleeding exist In patients with prosthetic Mitral or Aortic Valve consider FFP at 15mL/Kg In patients with Fontan circulation, other reasons for anticoagulation consider low dose Phytomenadione (Vitamin K1) 0 to 12 years: 5 to 10 microgram/ Kg by slow intravenous injection or 50 to 100 microgram/kg orally. Repeat dose if INR remains high after 24 hours Over 12 yrs: 500 micrograms by slow intravenous injection or 5mg orally. Repeat dose if INR remains high after 24 hours INR 6 to 8, no bleeding or minor bleeding Stop Warfarin, restart when INR is less than 5 INR is greater than 6 Reduce dose, restart warfarin when INR is less than 5 Unexpected bleeding at therapeutic levels Assess for local/ systemic cause of blood loss 10
11 References These Guidelines were written according to current practice and the following references: 1. Andrew M, Marzinotto K, Massicote P et al. Heparin Therapy in Paediatric Patients: A prospective cohort study Paediatric Research 1994; 35(1): Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines for use and monitoring of Heparin British Society of Haematology 2006; 133 : Dix D, Andrew M, Marizotto V et al. The use of low molecular weight heparin in paediatric patients: a prospective cohort study. Journal of Paediatrics 2000; 135: Maricotte P, Adams M, Marzinotto V et al. Low Molecular Weight Heparin in Paediatric Patients with thrombotic disease: a dose finding study. Journal of Paediatrics 1996, 128: Monagle P, Cochrane A, McCrindle B et al Thromboembolic complications after Fontan procedures- the role of prophylactic anticoagulation J Thorax Cardiovascular Surgery 1998, 115: Reller MD Congenital Heart Disease: Current Indications for Antithrombotic Therapy in Paediatric Patients Current Cardiology Reports 2001; 3: Richards M, Brooks T et al Protocol of use of anti-thrombotic treatment in children Leeds University Hospital Trust Guidelines Monagle P, Chan A et al. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of Chest Physicians evidence- based clinical practice guidelines Chest 2012; 141(2):e737s-e801s 9. Guidelines on oral anticoagulant with warfarin, Fourth Edition, British Journal of Haematology. 2011; 154: Written by: Teresa Brooks (Advanced Clinical Pharmacist for Paediatric Cardiology) Approved by: Paediatric Cardiology Clinical Governance Written: February 2014 Review date; October 2021 Last updated: October
Paediatric Anticoagulant Guidelines. Bhavee Patel, Gareth Thomas
Paediatric Anticoagulant Guidelines Author: Bhavee Patel, Gareth Thomas Specialty: Paediatrics Date Approved: 18 th July 2012 Approved by: W&CH Quality & Safety Group Date for Review: June 2015 PAEDIATRIC
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationAntithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki
Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationWarfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin
Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationGUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS
GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationReference Number: Revision No: Review Cycle:
Policy and Procedure for the management of patients presenting with excessive anticoagulation (INR>5.0) while on warfarin at the Cork University Hospital Group. Reference Number: Revision No: Review Cycle:
More information4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationAn Audit of the Post-Operative Management of Patients taking Warfarin
An Audit of the Post-Operative Management of Patients taking Warfarin Helen Wrightson Pre-Registration Pharmacist, Salisbury District Hospital March 2014 An Audit of the Post-Operative Management of Patients
More informationIntrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway
Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding
More informationANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY
ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationMANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS
Hairmyres Hospital MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Bleeding in patients on anticoagulants, even in the absence of over-anticoagulation, can be life-threatening
More informationAtlantic Provinces Pediatric Hematology/Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques
Atlantic Provinces Pediatric Hematology/Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques 5850/5980 University Avenue, PO Box 9700, Halifax, NS, B3K 6R8 (902) 470-8888
More information2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient
Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine
More informationGUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN
GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN Version Date Purpose of Issue/Description of Change Review Date 1 29/11/05 New Policy December 2007 2 Oct 07 Review Oct 09 3 March 10 Review
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital
ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity
More informationHoly Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH
Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients
More informationThromboprophylaxis in Patients with Congenital Heart Disease. Rachel Keashen, MSN, CRNP 10/19/2018
Thromboprophylaxis in Patients with Congenital Heart Disease Rachel Keashen, MSN, CRNP 10/19/2018 No disclosures/conflicts of interest COI Objectives Be able to name 2 thromboprophylaxis agents used to
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationPerioperative management of Anticoagulant and Antiplatelet medication GL067
Perioperative management of Anticoagulant and Antiplatelet medication GL067 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair, Anaesthetics Clinical November
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationDOCUMENT CONTROL PAGE
DOCUMENT CONTROL PAGE Title Title: UNDERGOING SPINAL DEFORMITY SURGERY Version: 2 Reference Number: Supersedes Supersedes: all other versions Description of Amendment(s): Revision of analgesia requirements
More informationHow to reverse warfarin
Page 1 of 5 How to reverse warfarin Index: Anticoagulation Original article by: Michael Tam Resources Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: In: By: For: Key words: Written by: All Clinical Areas All medical and nursing staff Adult patients requiring anticoagulation with warfarin
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationUsing an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy
Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy W. Sia, E. Toor, N. Wahab, J. Windram, R. Khurana Cardiac Problems in Pregnancy Congress
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationMANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas
MANAGEMENT OF OVER-ANTICOAGULATION Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas Risk of Intracranial Hemorrhage in Outpatients (From Management of Oral Anticoagulant
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationJoost van Veen Consultant Haematologist
Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationPackage leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )
Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationAntithrombotic Therapy in Neonates and Children
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy in Neonates and Children Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationIncorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose
Intravenous Heparin Therapy Initial Dose (Max Dose) IV Infusion Rate IV Infusion Rate (Max Dose) Lab Tests High Dose 80 units/kg 8,000 units 18 units/kg/hr 1,800 units/hr Intermediate Dose 5,000 units
More informationLAPAROSCOPIC PYELOPLASTY INFORMATION LEAFLET
LAPAROSCOPIC PYELOPLASTY INFORMATION LEAFLET Laparoscopic Pyeloplasty Page 1 of 8 LAPAROSCOPIC PYELOPLASTY This leaflet has been written to answers questions that you may have about your operation. If
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationTranscatheter Aortic Valve Implantation (TAVI) PROOF. Patient Information leaflet. Lancashire Cardiac Centre
Transcatheter Aortic Valve Implantation (TAVI) Patient Information leaflet Lancashire Cardiac Centre Welcome to the Lancashire Cardiac Centre During your admission you will be admitted to Ward 37. Ward
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationPatients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures
This is an official Northern Trust policy and should not be edited in any way Patients on anticoagulant or antiplatelet therapy undergoing elective endoscopic procedures Reference Number: NHSCT/11/454
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)
Approved by NPPEAG 18 December 2018 Reviewed 18 December 2018 To be reviewed 18 December 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Protocol for the Reversal
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS
ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, THROMBOLYTIC REVERSAL IN ADULT PATIENTS Several of the below interventions are based on low-level evidence and are intended as suggestions only.
More information(e.g. inclusion and exclusion criteria, diagnosis) anticoagulation Future management of HIT patients post acute phase
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline for the treatment of heparin induced thrombocytopenia (HIT) in adults
More information